H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Mediwound (MDWD – Research Report) today and set a price target of $5.50. The company’s shares closed last Monday at $3.17, close to its 52-week low of $2.55.
“We maintain our Buy rating and 12-month price target of $5.50 per share. We derive our price target based on an NPV analysis of projected future revenues from 2030, assuming an 11% discount rate and a 0.5% terminal growth rate.”
According to TipRanks.com, Ramakanth has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.7% and a 27.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.
Mediwound has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
Based on Mediwound’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.11 million. In comparison, last year the company had a GAAP net loss of $4.17 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture and commercialization of novel products to address needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders.